Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etavopivat in Sickle Cell Disease
NCT04624659Phase 3Active, not recruiting
- Sponsor
- Forma Therapeutics, Inc.
- Start
- Jan 2021
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of etavopivat in sickle cell disease (SCD) (4 arms), sponsored by Forma Therapeutics, Inc. Primary endpoints: Hemoglobin response rate at 24 weeks and Annualized vaso-occlusive crisis at 52 weeks. Started Jan 2021; status: active, not recruiting.
02
Drugs
etavopivat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04624659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624659.